Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INBX
1876
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $2.4M | ﹤0.01% |
92,300
-121,200
| -57% | -$2.83M |
|
1877
Lakeland Financial Corp
LKFN
$1.56B
| $2.4M | ﹤0.01% |
49,351
-1,005
| -2% | -$52.6K |
|
1878
Viemed Healthcare
VMD
$349M
| $2.39M | ﹤0.01% |
244,300
+68,900
| +39% | +$700K |
|
|
HEES
1879
DELISTED
H&E Equipment Services
HEES
| $2.39M | ﹤0.01% |
52,200
-47,532
| -48% | -$1.9M |
|
1880
Interparfums
IPAR
$3.7B
| $2.38M | ﹤0.01% |
17,600
+10,500
| +148% | +$1.47M |
|
1881
Alpha Pro Tech
APT
$55.7M
| $2.38M | ﹤0.01% |
597,486
-29,979
| -5% | -$118K |
|
1882
Hillman Solutions
HLMN
$1.71B
| $2.37M | ﹤0.01% |
263,429
+43,300
| +20% | +$361K |
|
1883
Eastern Company
EML
$154M
| $2.37M | ﹤0.01% |
130,837
+3,800
| +3% | +$66.8K |
|
1884
Castle Biosciences
CSTL
$933M
| $2.37M | ﹤0.01% |
172,400
+136,000
| +374% | +$2.76M |
|
|
IVAC
1885
DELISTED
Intevac Inc
IVAC
| $2.37M | ﹤0.01% |
630,577
+100,900
| +19% | +$541K |
|
1886
Banco Macro
BMA
$5.14B
| $2.36M | ﹤0.01% |
89,595
+31,417
| +54% | +$628K |
|
1887
Pangaea Logistics
PANL
$496M
| $2.36M | ﹤0.01% |
348,100
-56,600
| -14% | -$349K |
|
1888
Barclays
BCS
$94.6B
| $2.35M | ﹤0.01% |
+299,600
| New | +$2.32M |
|
1889
HealthEquity
HQY
$8.83B
| $2.35M | ﹤0.01% |
+37,300
| New | +$2.16M |
|
1890
Nektar Therapeutics
NKTR
$2.57B
| $2.35M | ﹤0.01% |
272,779
+72,533
| +36% | +$773K |
|
|
MREO
1891
Mereo BioPharma
MREO
$49.1M
| $2.35M | ﹤0.01% |
1,778,772
+862,863
| +94% | +$1M |
|
1892
Liquidia Corp
LQDA
$6.45B
| $2.35M | ﹤0.01% |
298,800
+129,200
| +76% | +$1M |
|
1893
Organogenesis Holdings
ORGO
$226M
| $2.34M | ﹤0.01% |
706,102
-542,298
| -43% | -$1.6M |
|
1894
Invesco S&P 500 Equal Weight ETF
RSP
$100B
| $2.33M | ﹤0.01% |
+15,600
| New | +$2.25M |
|
1895
RXO
RXO
$3.85B
| $2.33M | ﹤0.01% |
102,900
+55,000
| +115% | +$1.11M |
|
1896
Washington Trust Bancorp
WASH
$767M
| $2.33M | ﹤0.01% |
87,000
-3,100
| -3% | -$86.7K |
|
1897
Vivid Seats
SEAT
$80.5M
| $2.33M | ﹤0.01% |
+14,713
| New | +$2.29M |
|
1898
Altimmune
ALT
$560M
| $2.33M | ﹤0.01% |
658,700
+382,400
| +138% | +$1.72M |
|
1899
Invesco Actively Managed Exch-Traded Commodity Fd Tr Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF
PDBC
$6.61B
| $2.32M | ﹤0.01% |
170,534
+84,334
| +98% | +$1.17M |
|
|
KRTX
1900
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $2.32M | ﹤0.01% |
10,700
-103,200
| -91% | -$22.1M |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.